{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"16"}]}],"title":"Baseline PD-L1 expression ≥ 1%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"20"}]}],"title":"Baseline PD-L1 expression < 1%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"36"}]}],"title":"PD-L1 not quantifiable at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"Number of Participants with PD-L1 expression in the following categories\n\n* baseline PD-L1 expression ≥ 1%\n* baseline PD-L1 expression \\< 1%\n* without PD-L1 quantifiable at baseline","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"NUMBER","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"At baseline (prior to start of study treatment)","title":"Number of Participants With PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Number of Participants"}